Go To Global Site
Welcome to UCB in the United States

R&D pipeline

The UCB pipeline delivers:

  • a promising portfolio targeting severe diseases and addressing unmet medical needs
  • focus on neurological and immunological diseases
  • more convenient and effective treatments for patients and specialists.

UCB is connecting science in new ways to illuminate the biological pathways involved in severe diseases. Our researchers are developing a range of novel chemical entities (NCEs) and novel biological entities (NBE) to improve people’s lives.

Small molecule drug / NCE


Antibody-based drug / NBE



  Indications Phase 1 Phase 2 Phase 3 Filed
bimekizumab (IL17AF) psoriasis
  psoriatic arthritis
  axial spondyloarthritis
  hidradenitis suppurativa
rozanolixizumab (FcRn) myasthenia gravis
  immune thrombocytopenia
  chronic inflammatory demyelinating polyneuropathy (CIDP)
zilucoplan (C5) myasthenia gravis
  immune-mediated necrotizing myopathy (IMNM)
  amyotrophic lateral sclerosis1
  COVID-associated acute respiratory distress syndrome (ARDS)2
Staccato® alprazolam active epileptic seizure
dapirolizumab pegol (CD40L) systemic lupus erythematosus3
UCB0107 (Tau) progressive supranuclear palsy (PSP)
1 Project  
1 Project  


1 In partnership with HEALEY ALS Platform Trial
2 In partnership with University of Ghent (Belgium) & Medical Research Council (U.K.)
3 In partnership with Biogen


Information provided on this pages represents molecules currently under investigation and are not approved by any health authority worldwide.